• Browse Industries
• Health Care

• FDLI SmartBrief
• News
• Press Releases
• SmartBlogs
• Topics
• FDA
• Generic drugs
• Medical devices
• Nutrition
• Stem Cells
• Vaccines
• Jobs
• View Job Listings
• Post a Job
• Job Listings FAQ's
• Most Clicked Stories
• FDLI News
• FDLI Reader Polls
• Archive
• RSS

• Find/Post Jobs

• Partner With Us

• Advertise

• About SmartBrief

• Reader Polls

Stryker Biotech faces charges over off-label marketing of devices

Boston-based federal prosecutors filed an indictment against Stryker Biotech and some of its employees for allegedly marketing OP-1 Implant and OP-1 Putty -- devices used for spinal and long-bone surgeries -- for uses not approved by the FDA. Stryker Corp., the unit's parent company, said it "is disappointed with this action and still hopes to be able to reach a fair and just resolution to the matter."

Boston Herald | 10/28

This story published in FDLI SmartBrief on 10/29/2009

Get stories like these delivered daily for FREE:

FDLI SmartBrief Designed specifically for professionals involved in the food and drug industry, FDLI SmartBrief is a FREE daily e-mail newsletter. It provides the latest need-to-know news and industry information that maximizes your time, giving you an edge over your competition. Learn more